Abstract] Therapy-induced hypoxia drives changes in the tumor microenvironment that contribute to the poor response to therapy. Hypoxia is capable of driving the expression and/or activation of specific signaling cascades (e.g., c-Met, Axl, CTGF), the recruitment of tumor promoting immune cells, and the induction of cell survival pathways including autophagy (Phan et al., 2013; Hu et al., 2012; Ye et al., 2010) . We have recently shown that anti-VEGF therapyinduced hypoxia can result in changes in the extracellular matrix that contribute to the aggressiveness of tumors post therapy (Aguilera et al., 2014) . Importantly, therapies that induce hypoxia do not always increase epithelial plasticity and tumor aggressiveness Cenik et al., 2013) . We have used pimonidazole to evaluate hypoxia in tumors and herein provide a detailed protocol for this useful tool to interrogate the levels of hypoxia in vivo.
The utility of the Hypoxyprobe TM (pimonidazole hydrochloride) immunohistochemical analysis approach allows for the assessment of hypoxia in different tissues as well as cell types.
Pimonidazole is a 2-nitroimidazole that is reductively activated specifically in hypoxic cells and forms stable adducts with thiol groups in proteins, peptides, and amino acids  Arnold et al., 2010; Raleigh and Koch, 1990; Raleigh et al., 1998) . Furthermore, the amount of pimonidazole that is detected is directly proportional to the level of hypoxia within tumors. 
Materials and Methods

Hypoxyprobe
Procedure
The following procedure measures hypoxia in tumor-bearing mice and can be used at any respective end point of an animal experiment.
1. The Hypoxyprobe TM (pimonidazole hydrochloride) is resuspended at a concentration of 30 mg/ml in 0.9% sterile saline.
2. Multiple mice (n = 5 per group is optimal for statistical relevance) are injected intravenously (tail vein) with 60 mg/kg of the pimonidazole solution. b. For other primary antibodies a 1:50 -1:100 dilution is recommended, unless otherwise specified by respective primary antibody data sheets.
Notes: a. Any suitably labeled, secondary anti-FITC antibody can be used which would bind to the pimonidazole adducts in hypoxic cells within the tissues. b. This staining should be done within a week of harvesting the organs as the signal will begin to fade. c. The interrogation of hypoxia within animal tissues is not limited to fluorescent staining as it can be done with brown stain (DAB) as well. Respective primary and secondary
antibodies can be utilized to achieve both types of staining. 
